LISTA Mutagenicos Toxicos

MUTAGENICIDAD EN CÉLULAS GERMINALES Y TOXICIDAD PARA LA REPRODUCCIÓN
Index Noo International Chemical EC No CAS No Classification Labelling Specific Conc. Limits, Notes ATP
Identification Hazard Class and Hazard Pictogram, Hazard M-factors inserted/
Category Code(s) Statement Signal Word statement Suppl. Hazard ATP
Code(s) Code(s) Code(s) statement Code(s) Updated
005-006-00-7 dibutyltin hydrogen borate 401-040-5 75113-37-0 Repr. 1B H360FD GHS05 H360FD CLP00/ATP01
Muta. 2 H341 GHS08 H341
STOT RE 1 H372** GHS07 H372
Acute Tox. 4 * H312 GHS09 H312
Acute Tox. 4 * H302 Dgr H302
Eye Dam. 1 H318 H318
Skin Sens. 1 H317 H317
Aquatic Acute 1 H400 H410
Aquatic Chronic 1 H410
023-001-00-8 divanadium pentaoxide; 215-239-8 1314-62-1 Muta. 2 H341 GHS08 H341 CLP00/
vanadium pentoxide Repr. 2 H361d *** GHS07 H361d ***
STOT RE 1 H372 ** GHS09 H372 **
Acute Tox. 4 * H302 H302
STOT SE 3 H335 H335
Aquatic Chronic 2 H411 H411
024-001-00-0 chromium (VI) trioxide 215-607-8 1333-82-0 Ox. Sol. 1 H271 GHS03 H271 STOT SE 3; H335: C ≥ 1 % CLP00/
Carc. 1A H350 GHS06 H350
Muta. 1B H340 GHS08 H340
Repr. 2 H361f *** GHS05 H361f ***
STOT RE 1 H372 ** H372 **
Skin Corr. 1A H314 H314
Resp. Sens. 1 H334 H334
024-002-00-6 potassium dichromate 231-906-6 7778-50-9 Ox. Sol. 2 H272 GHS03 H272 STOT SE 3; H335: C ≥ 5 % 3 CLP00/
Carc. 1B H350 GHS06 H350
Repr. 1B H360FD GHS05 H360FD
STOT RE 1 H372 ** H372 **
Skin Corr. 1B H314 H314
Doc. PR/RL-10/0198-001/01
26 de octubre de 2010 1/15
024-003-00-1 ammonium dichromate 232-143-1 7789-09-5 Ox. Sol. 2 **** H272 GHS03 H272 STOT SE 3; H335: C ≥ 5 % G CLP00/
Carc. 1B H350 GHS06 H350 Resp. Sens.; H334: C ≥ 0,2 % 3
Muta. 1B H340 GHS08 H340 Skin Sens.; H317: C ≥ 0,2 %
STOT RE 1 H372 ** H372 **
024-004-00-7 sodium dichromate 234-190-3 10588-01-9 Ox. Sol. 2 H272 GHS03 H272 C ≥ 0,2 %: Resp. Sens. 1; H334 CLP00/ATP01
Carc. 1B H350 GHS06 H350 C ≥ 0,2 %: Skin Sens. 1; H317
Muta. 1B H340 GHS05 H340 C ≥ 5 %: STOT SE 3; H335
STOT RE 1 H372** H372**
024-018-00-3 sodium chromate 231-889-5 7775-11-3 Carc. 1B H350 GHS06 H350 Resp. Sens.; H334: C ≥ 0,2 % 3 CLP00/
Muta. 1B H340 GHS08 H340 Skin Sens.; H317: C ≥ 0,2 %
STOT RE 1 H372 ** H372 **
027-004-00-5 cobalt dichloride 231-589-4 7646-79-9 Carc. 1B H350i GHS08 H350i C ≥ 0,01 %: Carc. 1B; H350i 1 CLP00/ATP01
Muta. 2 H341 GHS07 H341 M=10
Repr. 1B H360F*** GHS09 H360F***
Doc. PR/RL-10/0198-001/01
027-005-00-0 cobalt sulfate 233-334-2 10124-43-3 Carc. 1B H350i GHS08 H350i C ≥ 0,01 %: Carc. 1B; H350i 1 CLP00/ATP01
Muta. 2 H341 GHS07 H341 M=10
Repr. 1B H360F*** GHS09 H360F***
027-006-00-6 cobalt acetate 200-755-8 71-48-7 Carc. 1B H350i GHS08 H350i C ≥ 0,01 %: Carc. 1B; H350i 1 ATP01/
Muta. 2 H341 GHS09 H341 M=10
Repr. 1B H360F*** Dgr H360F***
027-009-00-2 cobalt nitrate 233-402-1 10141-05-6 Carc. 1B H350i GHS08 H350i C ≥ 0,01 %: Carc. 1B; H350i 1 ATP01/
Muta. 2 H341 GHS09 H341 M=10
027-010-00-8 cobalt carbonate 208-169-4 513-79-1 Carc. 1B H350i GHS08 H350i C ≥ 0,01 %: Carc. 1B; H350i 1 ATP01/
Muta. 2 H341 GHS09 H341 M=10
028-008-00-X nickel dihydroxide; [1] 235-008-5 [1] 12054-48-7 [1] Carc. 1A H350i GHS08 H350i CLP00/ATP01
nickel hydroxide [2] 234-348-1 [2] 11113-74-9 [2] Repr. 1B H360D*** GHS07 H360D***
Muta. 2 H341 GHS09 H341
STOT RE 1 H372** Dgr H372**
Skin Irrit. 2 H315 H315
Doc. PR/RL-10/0198-001/01
028-009-00-5 nickel sulfate 232-104-9 7786-81-4 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H373 CLP00/ATP01
Muta. 2 H341 GHS07 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
Repr. 1B H360D*** GHS09 H360D*** C ≥ 20 %: Skin Irrit. 2; H315
STOT RE 1 H372** Dgr H372** C ≥ 0,01 %: Skin Sens. 1; H317
Acute Tox. 4 * H332 H332 M=1
028-010-00-0 nickel carbonate; 222-068-2 [1] 3333-67-3 [1] Carc. 1A H350i GHS08 H350i CLP00/ATP01
basic nickel carbonate; 240-408-8 [2] 16337-84-1 [2] Muta. 2 H341 GHS07 H341
carbonic acid, nickel (2+) salt; [1] 265-748-4 [3] 65405-96-1 [3] Repr. 1B H360D*** GHS09 H360D***
carbonic acid, nickel salt; [2] 235-715-9 [4] 12607-70-4 [4] STOT RE 1 H372** Dgr H372**
[µ-[carbonato(2-)-O :O ’]] dihydroxy trinickel; [3] Acute Tox. 4 * H332 H332
[carbonato(2-)] tetrahydroxytrinickel [4] Acute Tox. 4 * H302 H302
028-011-00-6 nickel dichloride 231-743-0 7718-54-9 Carc. 1A H350i GHS06 H350i C ≥ 1 %: STOT RE. 1; H373 ATP01/
Muta. 2 H341 GHS08 H341 0,1 % < C < 1 %: STOT RE. 2; H373
Repr. 1B H360D*** GHS09 H360D*** C ≥ 20 %: Skin Irrit. 2; H315
Acute Tox. 3 * H331 Dgr H331 C ≥ 0,01 %: Skin Sens. 1; H317
Acute Tox. 3 * H301 H301 M=1
STOT RE 1 H372** H372**
028-012-00-1 nickel dinitrate; [1] 236-068-5 [1] 13138-45-9 [1] Ox. Sol. 2 H272 GHS03 H272 C ≥ 1 %: STOT RE. 1; H373 ATP01/
nitric acid, nickel salt [2] 238-076-4 [2] 14216-75-2 [2] Carc. 1A H350i GHS05 H350i 0,1 % < C < 1 %: STOT RE. 2; H373
Muta. 2 H341 GHS08 H341 C ≥ 20 %: Skin Irrit. 2; H315
Repr. 1B H360D*** GHS07 H360D*** C ≥ 0,01 %: Skin Sens. 1; H317
STOT RE 1 H372** GHS09 H372** M=1
Aquatic Acute 1 H410
Aquatic Chronic 1
Doc. PR/RL-10/0198-001/01
028-014-00-2 slimes and sludges, copper electrolytic refining, decopperised,
295-859-3nickel sulfate
92129-57-2 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 ATP01/
STOT RE 1 H372** Dgr H372** M=1
028-015-00-8 slimes and sludges, copper electrolyte refining, decopperised

305-433-1 94551-87-8 Carc. 1A H350i GHS08 H350i H ATP01/
Muta. 2 H341 GHS09 H341
Repr. 1A H360D*** Dgr H360D***
STOT RE 1 H372** H372**
028-016-00-3 nickel diperchlorate; 237-124-1 13637-71-3 Carc. 1A H350i GHS05 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
perchloric acid, nickel(II) salt Muta. 2 H341 GHS08 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
STOT RE 1 H372** Dgr H372** M=1
028-017-00-9 nickel dipotassium bis(sulfate); [1] 237-563-9 [1] 13842-46-1 [1] Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
diammonium nickel bis(sulfate) [2] 239-793-2 [2] 15699-18-0 [2] Muta. 2 H341 GHS07 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
STOT RE 1 H372** Dgr H372** M=1
028-018-00-4 nickel bis(sulfamidate); 237-396-1 13770-89-3 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
nickel sulfamate Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
Repr. 1B H360D*** Dgr H360D*** C ≥ 0,01 %: Skin Sens. 1; H317
STOT RE 1 H372** H372** M=1
Doc. PR/RL-10/0198-001/01
028-019-00-X nickel bis(tetrafluoroborate) 238-753-4 14708-14-6 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-021-00-0 nickel diformate; [1] 222-101-0 [1] 3349-06-2 [1] Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
formic acid, nickel salt; [2] 239-946-6 [2] 15843-02-4 [2] Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
formic acid, copper nickel salt [3] 268-755-0 [3] 68134-59-8 [3] Repr. 1B H360D*** Dgr H360D*** C ≥ 0,01 %: Skin Sens. 1; H317
STOT RE 1 H372** H372** M=1
028-022-00-6 nickel di(acetate); [1] 206-761-7 [1] 373-02-4 [1] Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 EH ATP01/
nickel acetate [2] 239-086-1 [2] 14998-37-9 [2] Muta. 2 H341 GHS07 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
STOT RE 1 H372** Dgr H372** M=1
028-024-00-7 nickel dibenzoate 209-046-8 553-71-9 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-025-00-2 nickel bis(4-cyclohexylbutyrate) 223-463-2 3906-55-6 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 ATP01/
STOT RE 1 H372** H372** M=1
Doc. PR/RL-10/0198-001/01
028-026-00-8 nickel(II) stearate; 218-744-1 2223-95-2 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
nickel(II) octadecanoate Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
STOT RE 1 H372** H372** M=1
028-027-00-3 nickel dilactate - 16039-61-5 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-028-00-9 nickel(II) octanoate 225-656-7 4995-91-9 Carc. 1A H350i GHS05 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** Dgr H372** M=1
Skin Corr. 1A H314 H314
028-029-00-4 nickel difluoride; [1] 233-071-3 [1] 10028-18-9 [1] Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
nickel dibromide; [2] 236-665-0 [2] 13462-88-9 [2] Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
nickel diiodide; [3] 236-666-6 [3] 13462-90-3 [3] Repr. 1B H360D*** Dgr H360D*** C ≥ 0,01 %: Skin Sens. 1; H317
nickel potassium fluoride [4] - [4] 11132-10-8 [4] STOT RE 1 H372** H372** M=1
028-030-00-X nickel hexafluorosilicate 247-430-7 26043-11-8 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
Doc. PR/RL-10/0198-001/01
028-031-00-5 nickel selenate 239-125-2 15060-62-5 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-046-00-7 nickel dithiocyanate 237-205-1 13689-92-4 Carc. 1A H350i GHS08 H350i EUH032 C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-047-00-2 nickel dichromate 239-646-5 15586-38-6 Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
STOT RE 1 H372** H372** M=1
028-053-00-5 nickel dichlorate; [1] 267-897-0 [1] 67952-43-6 [1] Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
nickel dibromate; [2] 238-596-1 [2] 14550-87-9 [2] Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
ethyl hydrogen sulfate, nickel(II) salt [3] 275-897-7 [3] 71720-48-4 [3] Repr. 1B H360D*** Dgr H360D*** C ≥ 0,01 %1: Skin Sens. 1; H317
STOT RE 1 H372** H372** M=1
Doc. PR/RL-10/0198-001/01
028-054-00-0 nickel(II) trifluoroacetate; [1] ############# ################ Carc. 1A H350i GHS08 H350i C ≥ 1 %: STOT RE 1; H372 H ATP01/
nickel(II) propionate; [2] Muta. 2 H341 GHS09 H341 0,1 % ≤ C < 1 %: STOT RE 2; H373
nickel bis(benzenesulfonate); [3] Repr. 1B H360D*** Dgr H360D*** C ≥ 0,01 %: Skin Sens. 1; H317
nickel(II) hydrogen citrate; [4] STOT RE 1 H372** H372** M=1
citric acid, ammonium nickel salt; [5] Resp. Sens. 1 H334 H334
citric acid, nickel salt; [6] Skin Sens. 1 H317 H317
nickel bis(2-ethylhexanoate); [7] Aquatic Acute 1 H400 H410
2-ethylhexanoic acid, nickel salt; [8] Aquatic Chronic 1 H410
dimethylhexanoic acid nickel salt; [9]
nickel(II) isooctanoate; [10]
nickel isooctanoate; [11]
nickel bis(isononanoate); [12]
nickel(II) neononanoate; [13]
nickel(II) isodecanoate; [14]
nickel(II) neodecanoate; [15]
neodecanoic acid, nickel salt; [16]
nickel(II) neoundecanoate; [17]
bis(d-gluconato-O 1,O 2)nickel; [18]
nickel 3,5-bis(tert -butyl)-4-hydroxybenzoate (1:2);
[19]
nickel(II) palmitate; [20]
(2-ethylhexanoato-O )(isononanoato- O )nickel; [21]
(isononanoato-O )(isooctanoato- O )nickel; [22]
(isooctanoato-O )(neodecanoato- O )nickel; [23]
(2-ethylhexanoato-O )(isodecanoato- O )nickel; [24]
(2-ethylhexanoato-O )(neodecanoato- O )nickel; [25]
(isodecanoato-O )(isooctanoato- O )nickel; [26]
(isodecanoato-O )(isononanoato- O )nickel; [27]
(isononanoato-O )(neodecanoato- O )nickel; [28]
fatty acids, C6-19-branched, nickel salts; [29]
fatty acids, C8-18 and C18-unsaturated, nickel salts;
[30]
2,7-naphthalenedisulfonic acid, nickel(II) salt; [31]
048-002-00-0 cadmium (non-pyrophoric); [1] 231-152-8 [1] 7440-43-9 [1] Carc. 1B H350 GHS06 H350 CLP00/
cadmium oxide (non-pyrophoric) [2] 215-146-2 [2] 1306-19-0 [2] Muta. 2 H341 GHS08 H341
Repr. 2 H361fd GHS09 H361fd
STOT RE 1 H372 ** H372 **
Doc. PR/RL-10/0198-001/01
048-006-00-2 cadmium fluoride 232-222-0 7790-79-6 Carc. 1B H350 GHS06 H350 Carc. 1B; H350: C ≥ 0,01 % CLP00/
Muta. 1B H340 GHS08 H340 * oral
Repr. 1B H360FD GHS09 H360FD STOT RE 1; H372: C ≥ 7 %
Acute Tox. 2 * H330 Dgr H330 STOT RE 2: 0,1 % ≤ C < 7 %
STOT RE 1 H372 ** H372 **
048-008-00-3 cadmium chloride 233-296-7 10108-64-2 Carc. 1B H350 GHS06 H350 Carc. 1B; H350: C ≥ 0,01 % CLP00/
Acute Tox. 2 * H330 Dgr H330 STOT RE 2; H373: 0,1 % ≤ C < 7 %
STOT RE 1 H372 ** H372 **
048-009-00-9 cadmium sulphate 233-331-6 10124-36-4 Carc. 1B H350 GHS06 H350 Carc. 1B; H350: C ≥ 0,01 % CLP00/
Acute Tox. 2 * H330 Dgr H330 STOT RE 2; H373: 0,1 % ≤ C < 7 %
STOT RE 1 H372 ** H372 **
048-010-00-4 cadmium sulphide 215-147-8 1306-23-6 Carc. 1B H350 GHS08 H350 * 1 CLP00/
Muta. 2 H341 GHS07 H341 STOT RE 1; H372: C ≥ 10 %
Repr. 2 H361fd Dgr H361fd STOT RE 2; H373: 0,1 % ≤ C < 10 %
STOT RE 1 H372 ** H372 **
048-011-00-X cadmium (pyrophoric) 231-152-8 7440-43-9 Pyr. Sol. 1 H250 GHS02 H250 CLP00/
Muta. 2 H341 GHS08 H341
Repr. 2 H361fd GHS09 H361fd
STOT RE 1 H372 ** H372 **
Doc. PR/RL-10/0198-001/01
050-022-00-X dibutyltin dichloride; 211-670-0 683-18-1 Muta. 2 H341 GHS06 H341 C ≥ 5 %: Skin Corr. 1B; H314 ATP01/
(DBTC) Repr. 1B H360FD GHS05 H360FD 0,01 % ≤ C < 5 %: Skin Irrit. 2; H315
Acute Tox. 2 * H330 GHS08 H330 3 % ≤ C < 5 %: Eye Dam. 1; H318
Acute Tox. 3 * H301 GHS09 H301 0,01 % ≤ C < 3 %: Eye Irrit. 2; H319
Acute Tox. 4 * H312 Dgr H312 M=10
STOT RE 1 H372** H372**
080-010-00-X mercury dichloride; 231-299-8 7487-94-7 Muta. 2 H341 GHS06 H341 CLP00/ATP01
mercuric chloride Repr. 2 H361f*** GHS05 H361f***
STOT RE 1 H372** GHS09 H372**
Skin Corr. 1B H314 Dgr H314
601-032-00-3 benzo[a ]pyrene; 200-028-5 50-32-8 Carc. 1B H350 GHS08 H350 Carc. 1B; H350: C ≥ 0,01 % CLP00/
benzo[def ]chrysene Muta. 1B H340 GHS07 H340
Skin Sens. 1 H317 Dgr H317
602-021-00-6 1,2-dibromo-3-chloropropane 202-479-3 96-12-8 Carc. 1B H350 GHS06 H350 CLP00/
Repr. 1A H360F *** Dgr H360F ***
STOT RE 2 * H373 ** H373 **
603-038-00-1 allyl glycidyl ether; 203-442-4 106-92-3 Flam. Liq. 3 H226 GHS02 H226 CLP00/
allyl 2,3-epoxypropyl ether; Carc. 2 H351 GHS08 H351
prop-2-en-1-yl 2,3-epoxypropyl ether Muta. 2 H341 GHS05 H341
Repr. 2 H361f *** GHS07 H361f ***
STOT SE 3 H335 H335
Doc. PR/RL-10/0198-001/01
603-063-00-8 2,3-epoxypropan-1-ol; 209-128-3 556-52-5 Carc. 1B H350 GHS06 H350 CLP00/
glycidol; Muta. 2 H341 GHS08 H341
oxiranemethanol Repr. 1B H360F *** Dgr H360F ***
Eye Irrit. 2 H319 H319
STOT SE 3 H335 H335
603-143-00-2 R -2,3-epoxy-1-propanol 404-660-4 57044-25-4 Self-react. C **** H242 GHS02 H242 CLP00/
Muta. 2 H341 GHS08 H341
Repr. 1B H360F *** GHS05 H360F ***
603-211-00-1 2,3-epoxypropyltrimethylammonium chloride ...%; 221-221-0 3033-77-0 Carc. 1B H350 GHS05 H350 B ATP01/
glycidyl trimethylammonium chloride ...% Muta. 2 H341 GHS08 H341
Repr. 2 H361f*** GHS07 H361f***
STOT RE 2 * H373** H373**
604-076-00-1 phenolphthalein 201-004-7 77-09-8 Carc. 1B H350 GHS08 H350 Carc. 1A; H350: C ≥ 1 % ATP01/
Muta. 2 H341 Dgr H341
Repr. 2 H361f*** H361f***
604-082-00-4 2-chloro-6-fluoro-phenol 433-890-8 2040-90-6 Muta. 1B H340 GHS05 H340 ATP01/
Repr. 2 H361f*** GHS08 H361f***
Skin Corr. 1B H314 GHS09 H314
Skin Sens. 1 H317 Dgr H317
607-373-00-4 (±) tetrahydrofurfuryl (R )-2-[4-(6-chloroquinoxalin-2-yloxy)phenyloxy]propionate
414-200-4 119738-06-6 Muta. 2 H341 GHS08 H341 CLP00/
Repr. 1B H360Df GHS07 H360Df
STOT RE 2 * H373 ** Dgr H373 **
Doc. PR/RL-10/0198-001/01
609-007-00-9 2,4-dinitrotoluene; [1] 204-450-0 [1] 121-14-2 [1] Carc. 1B H350 GHS06 H350 CLP00/ATP01
dinitrotoluene [2] 246-836-1 [2] 25321-14-6 [2] Muta. 2 H341 GHS08 H341
Repr. 2 H361f*** GHS09 H361f***
STOT RE 2 * H373** H373**
609-049-00-8 2,6-dinitrotoluene 210-106-0 606-20-2 Carc. 1B H350 GHS06 H350 CLP00/

Muta. 2 H341 GHS08 H341
Repr. 2 H361f *** Dgr H361f ***
STOT RE 2 * H373 ** H373 **
Muta. 2 H341 GHS08 H341
Repr. 2 H361f *** GHS09 H361f ***
STOT RE 2 * H373 ** H373 **

Muta. 2 H341 GHS08 H341
Repr. 2 H361f *** GHS09 H361f ***
STOT RE 2 * H373 ** H373 **
Muta. 2 H341 GHS08 H341
Repr. 2 H361f *** Dgr H361f ***
STOT RE 2 * H373 ** H373 **
Doc. PR/RL-10/0198-001/01
Muta. 2 H341 GHS08 H341
Repr. 2 H361f *** GHS09 H361f ***
STOT RE 2 * H373 ** H373 **
609-065-00-5 2-nitrotoluene 201-853-3 88-72-2 Carc. 1B H350 GHS08 H350 CLP00/
Repr. 2 H361f *** GHS09 H361f ***
612-099-00-3 4-methyl-m -phenylenediamine; 202-453-1 95-80-7 Carc. 1B H350 GHS06 H350 CLP00/ATP01
2,4-toluenediamine Muta. 2 H341 GHS08 H341
Repr. 2 H361f*** GHS09 H361f***
STOT RE 2 * H373** H373**
612-151-00-5 methyl-phenylene diamine; - - Carc. 1B H350 GHS06 H350 CLP00/ATP01
diaminotoluene; Muta. 2 H341 GHS08 H341
[technical product – reaction mass of 4-methyl-m - Repr. 2 H361f*** GHS09 H361f***
phenylene diamine (EC No 202-453-1) and 2- Acute Tox. 3 * H301 Dgr H301
methyl-m -phenylene diamine (EC No 212-513-9)] Acute Tox. 4 * H312 H312
STOT RE 2 * H373** H373**
612-199-00-7 4,4'-oxydianiline and its salts; 202-977-0 101-80-4 Carc. 1B H350 GHS06 H350 CLP00/
p -aminophenyl ether Muta. 1B H340 GHS08 H340
Repr. 2 H361f *** GHS09 H361f ***
613-048-00-8 carbendazim (ISO); 234-232-0 10605-21-7 Muta. 1B H340 GHS08 H340 CLP00/
methyl benzimidazol-2-ylcarbamate Repr. 1B H360FD GHS09 H360FD
Aquatic Acute 1 H400 Dgr H410
Doc. PR/RL-10/0198-001/01
613-049-00-3 benomyl (ISO); 241-775-7 17804-35-2 Muta. 1B H340 GHS08 H340 M = 10 CLP00/
methyl 1-(butylcarbamoyl)benzimidazol-2- Repr. 1B H360FD GHS07 H360FD
ylcarbamate STOT SE 3 H335 GHS09 H335
Skin Irrit. 2 H315 Dgr H315
613-140-00-8 cycloheximide (ISO); 200-636-0 66-81-9 Muta. 2 H341 GHS06 H341 CLP00/
4-{}{(2R )-2-[(1S ,3S ,5S )-3,5-dimethyl-2- Repr. 1B H360D *** GHS08 H360D ***
oxocyclohexyl]-2-hydroxyethyl}}piperidine-2,6- Acute Tox. 2 * H300 GHS09 H300
dione Aquatic Chronic 2 H411 Dgr H411
616-003-00-0 acrylamide; 201-173-7 79-06-1 Carc. 1B H350 GHS06 H350 D CLP00/
prop-2-enamide Muta. 1B H340 GHS08 H340
Repr. 2 H361f *** Dgr H361f ***
STOT RE 1 H372 ** H372 **
616-148-00-X N -[6,9-dihydro-9-[[2-hydroxy-1-(hydroxymethyl)ethoxy]methyl]-6-oxo-1
424-550-1 84245-12-5 Carc. 1B H350 GHS08 H350 ATP01/
Muta. 1B H340 Dgr H340
Repr. 1B H360FD H360FD
Doc. PR/RL-10/0198-001/01

LISTA Mutagenicos Toxicos

Uploaded by

Copyright:

Available Formats

You might also like

LISTA Mutagenicos Toxicos

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

LISTA Mutagenicos Toxicos

Uploaded by

Copyright:

Available Formats

MUTAGENICIDAD EN CÉLULAS GERMINALES Y TOXICIDAD PARA LA REPRODUCCIÓN

028-015-00-8 slimes and sludges, copper electrolyte refining, decopperised

609-049-00-8 2,6-dinitrotoluene 210-106-0 606-20-2 Carc. 1B H350 GHS06 H350 CLP00/

609-051-00-9 3,4-dinitrotoluene 210-222-1 610-39-9 Carc. 1B H350 GHS06 H350 CLP00/

You might also like